Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of...

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• Limited pharmacotherapy breakthroughs exist for Chronic Obstructive Pulmonary Disease (COPD).
• Recent trials indicate potential benefits of biologic therapies for COPD patients.
• A comprehensive synthesis of evidence for biologics in COPD is currently lacking.

Purpose of the Study:

• To systematically review and meta-analyze randomized controlled trials of biologic medications in COPD patients.
• To evaluate the efficacy of biologics on exacerbations, FEV1, quality of life, and adverse events.
• To assess the certainty of evidence using the GRADE framework.

Main Methods:

• Systematic literature search of MEDLINE, EMBASE, and Cochrane CENTRAL up to July 17, 2024.
• Random effects frequentist network meta-analysis to compare biologic treatments.
• GRADE framework applied to assess the certainty of evidence for all outcomes.

Main Results:

• Dupilumab significantly reduced exacerbations compared to placebo (high certainty).
• Tezepelumab and dupilumab showed probable improvements in FEV1 above MCID in patients with high blood eosinophils (≥300/mcL).
• No biologic therapy demonstrated a clinically meaningful improvement in FEV1 for all COPD patients.

Conclusions:

• Dupilumab demonstrates efficacy in improving patient-relevant outcomes for COPD patients with elevated eosinophil counts.
• Other biologic therapies, such as tezepelumab, did not show significant effects on patient-relevant outcomes in this analysis.
• Biologic therapy, specifically dupilumab, represents a promising avenue for managing specific COPD patient subgroups.